MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT), today reported the start of THRIVE1, the company’s U.S. post-market clinical study of its Talent Thoracic Stent Graft for the endovascular repair of thoracic aortic aneurysms.
MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT), today reported the start of THRIVE1, the company’s U.S. post-market clinical study of its Talent Thoracic Stent Graft for the endovascular repair of thoracic aortic aneurysms.
